Pre-made Efungumab benchmark antibody ( scFv, anti-Heat Shock Protein 90 Homolog therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-167-1mg	1mg	3090
GMP-Bios-ab-167-10mg	10mg	Inquiry
GMP-Bios-ab-167-100mg	100mg	Inquiry
GMP-Bios-ab-167-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efungumab biosimilar, scFv: Anti-Heat Shock Protein 90 Homolog therapeutic antibody
INN Name	Efungumab
Target	Heat Shock Protein 90 Homolog
Format	scFv
Derivation	Human
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	NeuTec Pharma
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Breast cancer;Candidiasis
Development Tech	na